Qingdao Haier Biomedical Co Ltd (688139) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Qingdao Haier Biomedical Co Ltd (688139) has a cash flow conversion efficiency ratio of 0.002x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥7.33 Million ≈ $1.07 Million USD) by net assets (CN¥4.34 Billion ≈ $634.47 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 688139 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Qingdao Haier Biomedical Co Ltd - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Qingdao Haier Biomedical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Qingdao Haier Biomedical Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Qingdao Haier Biomedical Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Everi Holdings Inc
NYSE:EVRI
|
1.295x |
|
Playtika Holding Corp
NASDAQ:PLTK
|
-1.563x |
|
Jiangxi Guotai Civilian
SHG:603977
|
-0.035x |
|
Guizhou Qianyuan Power Co Ltd
SHE:002039
|
0.125x |
|
Jiangsu Bojun Industrial Technology Co. Ltd
SHE:300926
|
0.021x |
|
Zhejiang Chunhui Intelligent Control Co. Ltd.
SHE:300943
|
-0.001x |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
0.014x |
|
CSG Holding Co Ltd
SHE:000012
|
0.033x |
Annual Cash Flow Conversion Efficiency for Qingdao Haier Biomedical Co Ltd (2016–2025)
The table below shows the annual cash flow conversion efficiency of Qingdao Haier Biomedical Co Ltd from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see 688139 market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥4.62 Billion ≈ $676.52 Million |
CN¥267.89 Million ≈ $39.20 Million |
0.058x | -8.25% |
| 2024-12-31 | CN¥4.62 Billion ≈ $675.78 Million |
CN¥291.67 Million ≈ $42.68 Million |
0.063x | +12.50% |
| 2023-12-31 | CN¥4.44 Billion ≈ $649.71 Million |
CN¥249.26 Million ≈ $36.48 Million |
0.056x | -63.17% |
| 2022-12-31 | CN¥4.15 Billion ≈ $607.03 Million |
CN¥632.43 Million ≈ $92.54 Million |
0.152x | -12.28% |
| 2021-12-31 | CN¥3.64 Billion ≈ $532.46 Million |
CN¥632.43 Million ≈ $92.54 Million |
0.174x | -30.53% |
| 2020-12-31 | CN¥2.78 Billion ≈ $407.46 Million |
CN¥696.62 Million ≈ $101.94 Million |
0.250x | +119.32% |
| 2019-12-31 | CN¥2.46 Billion ≈ $359.82 Million |
CN¥280.49 Million ≈ $41.04 Million |
0.114x | -14.74% |
| 2018-12-31 | CN¥1.11 Billion ≈ $162.98 Million |
CN¥149.00 Million ≈ $21.80 Million |
0.134x | -44.55% |
| 2017-12-31 | CN¥614.76 Million ≈ $89.96 Million |
CN¥148.32 Million ≈ $21.70 Million |
0.241x | -20.99% |
| 2016-12-31 | CN¥722.81 Million ≈ $105.77 Million |
CN¥220.72 Million ≈ $32.30 Million |
0.305x | -- |
About Qingdao Haier Biomedical Co Ltd
Qingdao Haier Biomedical Co.,Ltd engages in the research and development, manufacture, marketing, and sale of low temperature storage equipment for biomedical samples in China and internationally. The company offers ULT freezers, pharmacy refrigerators, freezers, automatic storage solutions, cryogenics, active temperature controlled RKN containers, and RTMD products; and CO2 incubation, standard … Read more